



Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction: a comparative placebo-controlled study

Ahmad T. Motawi¹ · Sameh Fayek GamalEl Din¹ · Eslam M. Meatmed¹ · Ibrahim Fahmy¹

Received: 11 January 2024 / Accepted: 20 February 2024
© The Author(s) 2024

Abstract

Purpose We aimed to compare the efficacy, safety, and compliance of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film (ODF) in men with mild-to-moderate erectile dysfunction (ED).

Methods One hundred thirty-five randomized patients were equally divided into three groups according to age where each group included forty-five patients. Within each group, 15 patients received oral tadalafil 5 mg, 15 patients received ODF tadalafil 5 mg and 15 patients received a placebo once daily for 1 month. All participants were assessed by the validated Arabic version of the international index of erectile function (ArIIEF-5) at baseline and after 1 month. Also, the efficacy of different forms of tadalafil 5 mg was assessed by responding affirmatively to a questionnaire.

Results Patients aged > 25 to < 40 years and 40–55 years and > 55 years showed a statistically significant improvement of ArIIEF-5 scores after tadalafil 5 mg tablet and ODF tadalafil 5 mg compared to placebo ODF (23 ± 1.4 ; 22.7 ± 0.9 ; 20 ± 0.9 ; 20.4 ± 1.3 ; 20.2 ± 1.2 ; 16.6 ± 1.2 ; 18.5 ± 1.7 ; 19.6 ± 1.4 ; 16.3 ± 1.4 ; $p < 0.001$, respectively). Three patients (> 25 to < 40 years) who received tadalafil 5 mg tablet showed muscle and back pain. Gastrointestinal (GIT) upset (eight patients) followed by headache (seven patients) were the main side effects reported in patients (40–55 years) who received tadalafil 5 mg tablet. While GIT upset was the main side effect reported in patients (> 55 years) who received tadalafil 5 mg tablet.

Conclusion ODF tadalafil 5 mg is an effective, tolerable, and safe formulation that can be used in patients with mild-to-moderate ED.

Keywords Orodispersible film tadalafil · Tadalafil tablet · Erectile dysfunction

Introduction

Erectile dysfunction (ED) is a common condition that affects 20–40% of men between the ages of 60 and 69 years and more than 50% of men older than 70 years worldwide [1]. It affects around 20–30% of Egyptian married males [2]. Remarkably, the prevalence is projected to be 80% among patients with type 2 diabetes or metabolic syndrome [2]. Aging, depression, obesity, smoking, obstructive lung diseases, hypertension, dyslipidemia, socioeconomic class,

rural residency, quality of life, and COVID-19 infection are all factors contributing to increased incidence and prevalence of ED among the Egyptian population during the past decade [3–5]. The phosphodiesterase type 5 inhibitors (PDE5Is) sildenafil, tadalafil, vardenafil, and avanafil are the first line management of patients diagnosed with ED followed by self-administered intracorporal injection therapy using vasodilator drugs [6]. Moreover, surgical treatment of ED with multicomponent inflatable penile implants was associated with high satisfaction rates [6]. Brock and colleagues (2002) presented their initial data supporting the efficacy and safety of tadalafil [7]. Tadalafil was approved for use in Europe in late (2002), and in November (2003), it was approved by the FDA for use in the United States [7]. Tadalafil's molecular structure is different than similar structures of sildenafil and vardenafil [8]. Tadalafil is more

✉ Sameh Fayek GamalEl Din
samehfayek@kasralainy.edu.eg

¹ Department of Andrology and STDs Kasr Al-Ainy, Sexual Medicine & STIs Department, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo 11956, Egypt

selective for PDE5 than most other families of PDEIs [8]. Tadalafil had been developed as yellow film-coated tablets (FCTs) intended for oral administration [9]. They are available in several strengths, including 2.5 mg, 5 mg, 10 mg, or 20 mg. However, it is worth noting that this tablet formulation may provide challenges for patients with ED [9]. The oral dispersible film (ODF) is a novel type of medication delivery that consists of a small strip of thin polymeric film like a postage stamp in size [10].

The film rapidly disintegrates or dissolves when it is placed on the tongue, allowing for immediate drug release [10]. An ODF can rapidly dissolve and disintegrate within the oral cavity in less than 1 min [11]. The utilization of an ODF has demonstrated enhanced clinical efficacy of medications in comparison to conventional formulations such as tablets or capsules [12]. Enhancements to the taste and the performance of ODFs could be achieved by modifications to various constituents, such as film-forming polymers, active medicinal compounds, plasticizers, flavors, and sweeteners [10, 13]. ODF formulation could be taken without the need for water or chewing, which offered physicians and patients a novel and attractive option for the treatment of ED [14]. Furthermore, ODF formulation could provide a cost-effective alternative to conventional tablet formulation owing to recent developments in ODF manufacturing technology [14]. Thus, we conducted a single-blinded, randomized, placebo-controlled clinical trial to compare the efficacy, safety, and compliance to tadalafil 5 mg daily dose in the tablet form versus ODF in men with mild-to-moderate ED as they were given once daily for 1 month.

Patients and methods

The study protocol was approved by the local ethical committee of Kasr Alainy Faculty of Medicine. Approval was granted on December 2022 (MS-24-2023) that conforms to Helsinki Declaration 2013 [15]. All participants were recruited from October 2022 to August 2023. Also, they signed a written informed consent after discussing all study procedures, potential risks, and anticipated benefits.

Power of the study and sample size calculator was used for a non-inferiority randomized controlled study, with 0.05 alpha error and power of the study 0.80, 0.1 non-inferiority margin, and 2 enrollment ratios. Accordingly, 135 patients diagnosed with ED were needed to be enrolled and were randomized by simple numbering technique.

Inclusion criteria

Any married male patient ≥ 25 years old with regular heterosexual intercourse, 2–3 times/week in the previous 6 months

prior to enrollment in the study presenting with mild-to-moderate ED was included.

Exclusion criteria

Patients with diabetes, hypertension, metabolic syndrome, malabsorption syndrome, ischemic heart disease, atherosclerosis, vasculitis, major psychological problems, or Peyronie's disease were excluded from the current study. Those with post-priapism ED, a history of recent penile and/or urethral surgery or trauma, as well as uncorrected hypogonadism and contraindication to PDE5Is were excluded. Finally, patients who tried PDEIs and experienced side effects were also excluded from the study.

All patients who fulfilled the inclusion criteria were subjected to the following: medical and surgical histories were obtained from the participants. Furthermore, general and local examinations were done. All subjects answered a copy of the validated Arabic version of IIEF-5 (ArIIEF-5) separately at baseline and after 1 month [16]. Morning serum testosterone and prolactin (before 11 AM), total PSA (only in groups including men above 40 Y), glycosylated hemoglobin, random blood sugar, lipid profile were analyzed, and complete urine analysis was performed.

Patients were equally divided into 3 groups according to age where each group included 45 patients. Group A was > 25 to < 40 years, group B was 40 to 55 years, and group C was > 55 years. Within each group, 15 patients received oral tadalafil 5 mg tablet and 15 patients received ODF formulations of tadalafil 5 mg as well as 15 patients received an ODF placebo (hydroxy profile methyl cellulose polymer and starch) for 1 month. Moreover, the efficacy of different forms of tadalafil was assessed by responding affirmatively to the following questions: "Are you satisfied with the effect of treatment on your erections?" and "If yes, has treatment improved your ability to engage in sexual activity?" [17]. Finally, all patients were evaluated for the presence of adverse effects such as headache, dizziness, palpitation, gastrointestinal upset, and muscle or back pain on a scale from 1 to 10.

Statistical analysis

Data analysis was conducted using SPSS version 22nd; Qualitative data were presented by number and percentage, and quantitative data were presented by mean, standard deviation, minimum, and maximum. The Pearson Chi² test was used to compare categorical variables between groups. Quantitative variables were presented in mean, standard deviation, minimum, and maximum. The Kruskal–Wallis test was used to compare quantitative variables between study groups.

Results

Socio-demographic characteristics are presented in Table 1. Groups A, B, and C showed a statistically significant improvement in the ArIIIEF-5 scores after treatment with tadalafil 5 mg tablet and ODF tadalafil 5 mg compared to ODF placebo ($p < 0.001$) (Table 2, Fig. 1).

The efficacy of ODF tadalafil 5 mg and tadalafil 5 mg tablet was markedly higher compared to placebo ($p < 0.001$). Improvement in both formulations was reported in all patients compared to placebo across all groups. Compliance was significantly higher among patients on ODF tadalafil 5 mg compared to tadalafil 5 mg tablet in groups B and C, respectively ($p < 0.001$) (Table 2). Regarding adverse effects, muscle and back pains were significantly higher among patients receiving tadalafil 5 mg tablet compared to other formulations in group A ($p = 0.040$) (Table 2). While headache, gastrointestinal (GIT) upset, and muscle and back pains were significantly reported among patients receiving tadalafil 5 mg tablet compared to other formulations in group B ($p < 0.001$, < 0.001 , and 0.012 , respectively) (Table 2). Finally, GIT upset was significantly reported among patients receiving tadalafil 5 mg tablet compared to other formulations in group C ($p < 0.001$) (Table 2).

Discussion

The core findings of the current study were that participants across all groups showed a statistically significant improvement in the ArIIIEF-5 scores after tadalafil 5 mg tablet and ODF tadalafil 5 mg compared to ODF placebo. Furthermore, post hoc analysis showed that improvement after tadalafil 5 mg tablet and ODF tadalafil 5 mg was mainly significant compared to placebo, and both formulations were comparable in efficacy. Patients who received ODF tadalafil 5 mg were significantly more compliant to treatment compared to tadalafil 5 mg tablet.

In contrast, Park et al. (2018) stated that safety and tolerability features of the ODF formulation were found to be comparable to those of the film-coated tablet formulation [18]. Furthermore, the same aforementioned study conducted by Park et al. (2018) [18] reported no serious adverse events in the study arms, either in oral tablet tadalafil or ODF tadalafil [18], which could also be seen as contradictory to our findings. In the same context, Cocci et al. (2017) [19] revealed that sildenafil ODF exhibited comparable levels of safety and efficacy to the conventional film-coated tablet [19]. However, the aforementioned study revealed that the ODF formulation elicited greater overall satisfaction among the patients [19], which could be seen as similar to

Table 1 Sociodemographic characteristics among participants

		Group A > 25 to < 40 years		Group B 40 to 55 years		Group C > 55 years		P value
		Count	%	Count	%	Count	%	
Special habits	Ex-smoker	3	6.7%	3	6.7%	5	11.1%	0.466
	Non-smoker	25	55.6%	15	33.3%	18	33.3%	0.039
	Smoker	17	37.8%	27	60.0%	22	46.7%	0.030
Spouse age		27.1 ± 3.7	19–33	43.1 ± 4.7	32–50	48.7 ± 3.4	39–56	< 0.001
Duration of the complaint (months)		7.2 ± 8.9	1–36	13.8 ± 10.8	2–48	52.8 ± 41.2	3–120	< 0.001
Surgical history	Anal fistulectomy	0	0.0%	1	2.2%	0	0%	0.081
	Appendectomy	2	4.4%	3	6.7%	0	0.0%	
	Bil HLO	0	0.0%	3	6.7%	0	0.0%	
	Hemorrhoidectomy	1	2.2%	3	6.7%	0	0.0%	
	Hernioplasty	0	0.0%	1	2.2%	0	0.0%	
	Laryngeal operation	0	0.0%	0	0.0%	1	2.2%	
	Nephrolithotomy	1	2.2%	1	2.2%	0	0.0%	
	Ophthalmology operation	0	0.0%	0	0.0%	1	2.2%	
	Pelvic fracture	0	0.0%	1	2.2%	0	0.0%	
	Piles	0	0.0%	2	4.4%	0	0.0%	
	Pilonidal sinus	0	0.0%	1	2.2%	0	0.0%	
	Rectal prolapse	0	0.0%	1	2.2%	0	0.0%	
	Road traffic accident	0	0.0%	1	2.2%	0	0.0%	
	Testicular biopsy	1	2.2%	0	0.0%	0	0.0%	
	Free	40	88.9%	27	60.0%	43	95.5%	

Table 2 Comparison between ArHIEF-5 improvement, efficiency, compliance, and safety among participants according to age groups

	Placebo ODF			Tadalafil ODF			Tadalafil tablet			P value
	Mean ± SD	Min–Max		Mean ± SD	Min–Max		Mean ± SD	Min–Max		
Efficacy	ArHIEF-5 score before treatment	19.6 ± 1.2	18–22	19.5 ± 1.2	17–22		19.5 ± 1.4	17–22		0.99
	ArHIEF-5 score after treatment	20 ± 0.9	19–22	22.7 ± 0.9	20–24		23 ± 1.4	20–24		<0.001
	ArHIEF-5 score before treatment	16.2 ± 0.9	15–18	16.7 ± 0.9	15–18		17 ± 1.3	15–19		0.171
Group B (40 to 55 years)	ArHIEF-5 score after treatment	16.6 ± 1.2	15–19	20.2 ± 1.2	18–23		20.4 ± 1.3	18–22		<0.001
	ArHIEF-5 score before treatment	16.3 ± 1.4	14–19	16.1 ± 1.4	14–19		15.5 ± 1.4	13–18		0.323
	ArHIEF-5 score after treatment	16.3 ± 1.4	14–19	19.6 ± 1.4	17–22		18.5 ± 1.7	16–21		<0.001
Group A (> 25 to < 40 years)	Efficient	5	33.3%	15	100%	15		100%		<0.001
	Not efficient	10	66.7%	0	0%	0		0%		
	Efficient	6	40%	15	100%	15		100%		0.001
Group B (40 to 55 years)	Not efficient	9	60%	0	0%	0		0%		
	Efficient	0	0%	15	100%	15		100%		<0.001
	Not efficient	15	100%	0	0%	0		0%		
Compliance	Compliant	15	100%	15	100%	15		100.0%		NA
	Not compliant	0	0%	0	0%	0		0.0%		
	Compliant	15	100%	15	100%	5		33.3%		<0.001
Group B (40 to 55 years)	Not compliant	0	0%	0	0%	10		66.7%		
	Compliant	15	100%	15	100%	9		60.0%		<0.001
	Not compliant	0	0%	0	0%	6		40.0%		
Adverse effects	Muscle or back pain	0	0%	0	0%	3		20.0%		0.04
	Headache	0	0%	0	0%	7		46.7%		<0.001
	GIT upset	0	0%	0	0%	8		53.3%		<0.001
Group A (> 25 to < 40 years)	Muscle or back pain	0	0%	0	0%	4		26.7%		0.012
	Headache	0	0%	0	0%	6		40.0%		0.001
	GIT upset	0	0%	0	0%	2		13.3%		0.123

N.B ODF oral dispersible film, GIT upset gastrointestinal upset




Fig. 1 Box plot showing ArIIEF-5 score post-treatment and improvement compared to baseline among age groups according to intervention

our findings. In the same context, the prevalence of headache in ODF decreased, and the duration and intensity of flushing and nasal congestion were lower in a study conducted by De Toni et al. (2018) [20] that could be seen in agreement with the current findings. Although both formulations

demonstrated comparable efficacy in the current study, yet, the ODF tadalafil 5 mg formulation demonstrated lesser side effects as well as better tolerability. Henceforth, the findings of the current study could be postulated that a rapid ODF pre-gastric absorption resulted in a faster onset of action

with subsequent enhanced bioavailability and therapeutic outcomes as well as reduced dosing and adverse effects [21]. Furthermore, the safety profiles could be enhanced by lowering toxic metabolites that resulted from hepatic metabolism since the drug was mostly absorbed from buccal mucosa [14]. The main limitation of the current study was the relatively small sample size per group. Also, the inability to measure the serum levels of both formulations to evaluate the pharmacokinetic properties can be added as a limitation.

Finally, exclusion of patients with serious medical comorbidities which might have interfered with the effectiveness of each drug formulation can be regarded as another limitation. However, it should be emphasized that we did not need to monitor any potential side effects from both formulations of tadalafil 5 mg administration especially cardiovascular complications since patients with severe ED and associated serious comorbidities were excluded from the study as mentioned in the previous limitation. Furthermore, it is worth mentioning that proper diagnosis and treatment of ED as well as its risk factors optimize control and management of any associated comorbidity with ED [22]. Eventually, large prospective studies should be conducted to assess the prevalence and severity of adverse events of tadalafil tablets compared to ODF and to assess the difference of tadalafil tablets among patients with organic ED due to medical comorbidities, metabolic and malabsorption syndromes.

Conclusion

ODF tadalafil 5 mg is an effective, tolerable, and safe drug formulation that can be used regularly or on-demand exactly as tadalafil 5 mg tablets with lesser adverse events and higher compliance rates.

Acknowledgements We would like to thank Nerhadou International Pharmaceutical Company, which provided us with the ODF tadalafil 5 mg as well as the ODF placebo. At the same time, the patients bought the tablet form on their own.

Author contributions SFGD: drafted the manuscript. IF and AM: developed the concept and study design. AM and IM recruited the cases and performed the statistics of the study.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the local ethical committee.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Shamloul R, Ghanem H (2013) Erectile dysfunction. *Lancet* 381(9861):153–165
2. Salama MN, Eid AA, Hatem A, Swidan AK (2020) Prevalence of erectile dysfunction in Egyptian males with metabolic syndrome. *Aging Male* 23(4):257–263
3. Zedan H, Hareadei AA, Abdel Sayed AA, Abdel Maguid EM (2010) Cigarette smoking, hypertension and diabetes mellitus as risk factors for erectile dysfunction in upper Egypt. *EMHJ-East Mediterr Health J* 16(3):281–285
4. Saad HM, GamalEl Din SF, Elbokl OM, Adel A (2022) Predictive factors of erectile dysfunction in Egyptian individuals after contracting COVID-19: a prospective case–control study. *Andrologia* 54(1):e14308
5. Kamal EE, Zedan HM, Ismail AA, Hussein K, Zakaria M, Badran AY (2021) Erectile dysfunction in Egyptian patients with chronic obstructive pulmonary disease. *Egypt J Dermatol Venerol* 41(1):38
6. McMahon CG (2019) Current diagnosis and management of erectile dysfunction. *Med J Aust* 210(10):469–476
7. Brock GB, McMahon CG, Chen KK et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. *J Urol* 168(4 Pt 1):1332–1336
8. Coward RM, Carson CC (2008) Tadalafil in the treatment of erectile dysfunction. *Ther Clin Risk Manag* 4(6):1315–1330
9. Curran MP, Keating GM (2003) Tadalafil. *Drugs* 63:2203–2212
10. Hoffmann EM, Breitenbach A, Breikreutz J (2011) Advances in orodispersible films for drug delivery. *Expert Opin Drug Deliv* 8(3):299–316
11. Ketul P, Patel KR, Patel MR, Patel NM (2013) Fast dissolving films: a novel approach to oral drug delivery. *IJTP* 4(2):655–661
12. Dixit RP, Puthli SP (2009) Oral strip technology: overview and future potential. *J Control Release* 139(2):94–107
13. Amin PM, Gangurde AB, Alai PV (2015) Oral film technology: challenges and future scope for pharmaceutical industry. *Int J Pharm Pharm Res* 3(3):184–203
14. Bala R, Pawar P, Khanna S, Arora S (2013) Orally dissolving strips: a new approach to oral drug delivery system. *Int J Pharma Investig* 3:67–76

15. World Medical Association (2013) World medical association declaration of helsinki: ethical principles for medical research involving human subjects. *JAMA* 310(20):2191–2194. <https://doi.org/10.1001/jama.2013.281053>
16. Shamloul R, Ghanem H, Abou-zeid A (2004) Validity of the arabic version of the sexual health inventory for men among Egyptians. *Int J Impot Res* 16(5):452–455
17. McMurray JG, Feldman RA, Auerbach SM, Deriesthal H, Wilson N; Multicenter Study Group (2007) Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. *Ther Clin Risk Manag* 3(6):975–981
18. Park S-I, Heo S-H, Kim G et al (2018) Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet. *Drug Des Dev Ther* 12:935–942
19. Cocci A, Capece M, Cito G et al (2017) Effectiveness and safety of oro-dispersible sildenafil in a new film formulation for the treatment of erectile dysfunction: comparison between sildenafil 100 mg film-coated tablet and 75 mg oro-dispersible film. *J Sex Med* 14(12):1606–1611
20. De Toni L, De Rocco PM, Franceschinis E et al (2018) Sublingual administration of sildenafil oro-dispersible film: new profiles of drug tolerability and pharmacokinetics for pde5 inhibitors. *Front Pharmacol* 9:59
21. Refaat A, Sokar M, Ismail F, Boraie N (2015) Tadalafil oral disintegrating tablets: an approach to enhance tadalafil dissolution. *J Pharm Investig* 45(5):481–491. <https://doi.org/10.1007/s40005-015-0196-x>
22. Scranton RE, Goldstein I, Stecher VJ (2013) Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. *J Sex Med* 10(2):551–561. <https://doi.org/10.1111/j.1743-6109.2012.02998.x>. (Epub 2012 Nov 15 PMID: 23153075)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.